Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC

This study has been completed.
University Hospital of Crete
Information provided by (Responsible Party):
Hellenic Oncology Research Group Identifier:
First received: January 31, 2008
Last updated: June 24, 2014
Last verified: June 2014